Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;37(2):265-273.
doi: 10.1002/ncp.10830. Epub 2022 Feb 6.

Beyond lipids: Novel mechanisms for parenteral nutrition-associated liver disease

Affiliations
Review

Beyond lipids: Novel mechanisms for parenteral nutrition-associated liver disease

Brittany E Wichman et al. Nutr Clin Pract. 2022 Apr.

Abstract

Parenteral nutrition (PN) is a therapy that delivers essential nutrients intravenously to patients who are unable to meet their nutrition requirements via standard enteral feeding. This methodology is often referred to as PN when accompanied by minimal or no enteral nutrition (EN). Although PN is lifesaving, significant complications can arise, such as intestinal failure-associated liver disease and gut-mucosal atrophy. The exact mechanism of injury remains ill defined. This review was designed to explore the available literature related to the drivers of injury mechanisms. The Farnesoid X receptor and fibroblast growth factor 19 signaling pathway seems to play an important role in gut-systemic signaling, and its alteration during PN provides insights into mechanistic links. Central line infections also play a key role in mediating PN-associated injury. Although lipid reduction strategies, as well as the use of multicomponent lipid emulsions and vitamin E, have shown promise, the cornerstone of preventing injury is the early establishment of EN.

Keywords: Farnesoid X receptor; enteral nutrition; fibroblast growth factor-19; intestinal failure; liver disease; parenteral nutrition.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

None

References

    1. Guzman M, Manithody C, Krebs J, et al. Impaired gut–systemic signaling drives total parenteral nutrition-associated injury. Nutrients. 2020;12(5). doi: 10.3390/nu12051493 - DOI - PMC - PubMed
    1. Price A, Blomenkamp K, Manithody C, et al. Developing a Novel Ambulatory Total Parenteral Nutrition-Dependent Short Bowel Syndrome Animal Model. J Surg Res. 2019;234:13–19. doi: 10.1016/j.jss.2018.08.042 - DOI - PMC - PubMed
    1. Jain AK, Stoll B, Burrin DG, Holst JJ, Moore DD. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. Am J Physiol - Gastrointest Liver Physiol. 2012;302(2):2021. doi: 10.1152/ajpgi.00280.2011 - DOI - PMC - PubMed
    1. Dudrick SJ, Palesty JA. Historical Highlights of the Development of Total Parenteral Nutrition. Surg Clin North Am. 2011;91(3):693–717. doi: 10.1016/j.suc.2011.02.009 - DOI - PubMed
    1. Javid PJ, Greene AK, Garza J, et al. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg. 2005;40(9):1446–1453. doi: 10.1016/j.jpedsurg.2005.05.045 - DOI - PubMed

MeSH terms